Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) - Pipeline Review, H1 2016

  • ID: 3788889
  • Report
  • 59 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Allergan Plc
  • Brickell Biotech, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Oxagen Limited
  • Pulmagen Therapeutics LLP
  • MORE
Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) - Pipeline Review, H1 2016

Summary

‘Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) - Pipeline Review, H1 2016’, provides in depth analysis on Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) targeted pipeline therapeutics.

The report provides comprehensive information on the Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2)
- The report reviews Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Allergan Plc
  • Brickell Biotech, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Oxagen Limited
  • Pulmagen Therapeutics LLP
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) Overview

Therapeutics Development

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) - Products under Development by Stage of Development

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) - Products under Development by Therapy Area

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) - Products under Development by Indication

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) - Products under Development by Companies

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) - Companies Involved in Therapeutics Development

Allergan Plc

Brickell Biotech, Inc.

Ligand Pharmaceuticals, Inc.

Merck & Co., Inc.

Novartis AG

Oxagen Limited

Panmira Pharmaceuticals, LLC.

Pulmagen Therapeutics LLP

Taisho Pharmaceutical Holdings Co., Ltd.

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) - Drug Profiles

ADC-3680 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADC-7405 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADC-9971 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-211 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-461 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BBI-5000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fevipiprant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-1029 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OC-000459 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OC-2417 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

setipiprant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TASP-0376377 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) - Dormant Projects

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) - Discontinued Products

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) - Featured News & Press Releases

Sep 22, 2015: KYTHERA Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss

Jun 16, 2015: Atopix Therapeutics Secures Funding to Broaden Development of CRTH2 Antagonists for TH2-Mediated Disease

Aug 01, 2014: Pulmagen’s lead CRTh2 antagonist, ADC3680, completes patient recruitment in Phase II study

Mar 03, 2014: Atopix Therapeutics Announces Positive Phase IIb Results for Once Daily OC459 in Asthma

Nov 19, 2013: Atopix Therapeutics Recruits First Patient in Phase 2 Trial of OC459 for Atopic Dermatitis

May 29, 2013: Atopix Therapeutics Receives Biomedical Catalyst Grant To Pursue Development Of OC459 In Treatment Of Atopic Dermatitis

Jul 15, 2011: Oxagen Announces Publication Of Phase IIa Asthma Trial Data For OC000459 Which Shows Promise As New Oral Treatment For Asthma And Related Disorders

May 23, 2011: Actelion's CRTH2 Antagonist Meets primary Endpoint In Phase II Study In Patients With Seasonal Allergic Rhinitis

May 26, 2010: Amira Announces Second DP2 Antagonist Patent Grant In UK

Dec 09, 2009: Oxagen Announces Completion Of Recruitment In Phase IIb Dose Range-Finding Clinical Trial In New Oral Treatment For Asthma

Dec 09, 2009: Oxagen Completes Recruitment Of Patients For Phase IIb Clinical Trial Of OC000459 For Asthma

Dec 03, 2009: Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data Of AM461

Dec 03, 2009: Amira Pharmaceuticals Announces Phase 1 Clinical Results Of AM461, For The Novel Treatment Of Asthma, Chronic Obstructive Pulmonary Disease (COPD) And Allergic Rhinitis.

Aug 18, 2009: Amira Pharmaceuticals Submits IND For AM461

Jun 30, 2009: Amira Pharmaceuticals Announces Initial Positive Phase I Clinical Data For AM211

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 59List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Allergan Plc, H1 2016

Pipeline by Brickell Biotech, Inc., H1 2016

Pipeline by Ligand Pharmaceuticals, Inc., H1 2016

Pipeline by Merck & Co., Inc., H1 2016

Pipeline by Novartis AG, H1 2016

Pipeline by Oxagen Limited, H1 2016

Pipeline by Panmira Pharmaceuticals, LLC., H1 2016

Pipeline by Pulmagen Therapeutics LLP, H1 2016

Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Dormant Projects (Contd..2), H1 2016

Discontinued Products, H1 2016 49List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Allergan Plc
  • Brickell Biotech, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Oxagen Limited
  • Pulmagen Therapeutics LLP
  • MORE
According to our recently published report 'Prostaglandin D2 Receptor 2 – Pipeline Review,'; Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) pipeline Target constitutes close to 13 molecules. Out of which approximately 13 molecules are developed by Companies.

Furthermore, the publisher says; Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) Prostaglandin D2 (PGD2) receptors are G protein-coupled receptors that binds and is activated by prostaglandin D2. It mediates the pro-inflammatory chemotaxis of eosinophils, basophils, and Th2 lymphocytes generated during allergic inflammation.

The report 'Prostaglandin D2 Receptor 2 – Pipeline Review,' outlays comprehensive information on the Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Prostaglandin D2 Receptor 2 (Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells or G-Protein Coupled Receptor 44 or CD294 or DP2 or PTGDR2) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 4, 1, 3 and 1 respectively.
Note: Product cover images may vary from those shown
5 of 6
Allergan Plc
Brickell Biotech, Inc.
Ligand Pharmaceuticals, Inc.
Merck & Co., Inc.
Novartis AG
Oxagen Limited
Panmira Pharmaceuticals, LLC.
Pulmagen Therapeutics LLP
Taisho Pharmaceutical Holdings Co., Ltd.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll